Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

This is an interventional treatment trial for Adenocarcinoma of the Prostate Read More

Inclusion Criteria:

• Histologically confirmed prostate cancer

  • Stage D0 OR D1 disease (i.e., tumor originally diagnosed as being limited to the prostate and regional lymph nodes)
  • Has a rising PSA value after definitive local therapy (i.e., prostatectomy or radiotherapy) and no radiographic evidence of disease

• PSA progression after local treatment:

  • PSA values for patients after surgery must be ≥ 0.2 ng/mL, determined by two measurements, ≥ 1 month apart and ≥ 6 months after prostatectomy
  • PSA values for patients after radiotherapy must be ≥ 2.0 ng/mL above the nadir PSA achieved after radiotherapy, determined by two measurements at 1 month apart and ≥ 6 months after completion of the radiotherapy treatment (patients who received adjuvant or salvage radiotherapy after prostatectomy must have PSA of ≥ 0.2 ng/mL)
  • The first two PSA values, along with a third (study baseline) value must all be rising (i.e., there must be an overall rising trajectory, such that the third value cannot be lower than the first value)
• No metastatic disease on baseline bone scan and CT scan of the abdomen/pelvis
• ECOG performance status 0-2
• Life expectancy ≥ 6 months
• WBC ≥ 3,000/mm^3
• ANC ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 9 g/dL
• Serum creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance ≥ 40 mL/min for patients with creatinine levels above normal
• Bilirubin normal
• AST and/or ALT ≤ 2.5 times ULN
• Serum total testosterone level ≥ 150 ng/dL
• No uncontrolled electrolyte abnormalities including hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or hypokalemia, defined as less than the lower limit of normal despite adequate electrolyte supplementation
• Fertile patients must use two effective forms of contraception (i.e., barrier contraception and one other method of contraception) for 1 week before, during, and for ≥ 12 months after completion of study treatment
• Able to swallow tablets
• No malabsorption syndrome or other condition that would interfere with intestinal absorption

• No uncontrolled concurrent illness including, but not limited to, any of the following:

  • Ongoing or active infection
  • Symptomatic congestive heart failure
  • Unstable angina pectoris
  • A history of torsades de pointes
  • Cardiac arrhythmia other than chronic, stable atrial fibrillation
  • Psychiatric illness or social situation that would limit compliance with study requirements
• Baseline QTc ≤ 450 msec
• No serologic positivity for acute hepatitis A, acute or chronic hepatitis B, or acute or chronic hepatitis C
• No history of liver disease or other forms of hepatitis or cirrhosis
• No HIV-positive patients on combination antiretroviral therapy
• No serious concurrent systemic disorder that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator
• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma-secretase inhibitor RO4929097 or bicalutamide
• Patients may not donate sperm or blood during or for ≥ 12 months after completion of study treatment
• No concurrent medications or food that may interfere with the metabolism of RO4929097 including grapefruit and fresh-squeezed grapefruit juice
• Recovered from adverse events to < CTCAE grade 2

• At least 3 months since prior and no concurrent androgen-deprivation therapy (ADT)

  • Hormone-ablative treatment is only allowed in the neoadjuvant setting or in the setting of primary or salvage radiotherapy
  • No more than 36 months of neoadjuvant/ adjuvant ADT
• More than 4 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas or mitomycin C)
• More than 4 weeks since prior and no concurrent estrogens, estrogen-like substances (i.e., PC-SPES, saw palmetto, or other herbal product that may contain phytoestrogens), or any other hormonal therapy (including flutamide, nilutamide, finasteride, ketoconazole, systemic corticosteroids, megestrol acetate, or cyproterone acetate)
• No other concurrent investigational agents
• No concurrent medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®)
• No concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4
• No other investigational or commercial agents or therapies administered with the intent to treat the patient's malignancy, including chemotherapy, immunotherapy, hormonal cancer therapy, radiotherapy, or surgery for cancer
• No concurrent hormonal therapy with a leuteinizing hormone-releasing hormone (LHRH) agonist therapy (e.g., leuprolide or goserelin) or LHRH antagonist (e.g., abarelix)
• No concurrent growth factors (e.g., G-CSF), packed RBC transfusions, or platelet transfusions
• No concurrent antiarrhythmics or other medications known to prolong QTc